Publisher
Springer Science and Business Media LLC
Subject
Public Health, Environmental and Occupational Health,Health Policy,Pharmacology
Reference38 articles.
1. Kearns B. NICE DSU report. The relevance of future, unrelated health costs in economic evaluation in NICE appraisals. Decision Support Unit, ScHARR, University of Sheffield, 2020. http://www.nicedsu.org.uk/wp-content/uploads/2020/11/Future_unrelated_costs_Final.pdf.
2. Morton A, et al. Unrelated future costs and unrelated future benefits: reflections on NICE guide to the methods of technology appraisal. Health Econ. 2016;25(8):933–8. https://doi.org/10.1002/hec.3366.
3. van Baal P, Morton A, Meltzer D, Brouwer W. Future unrelated medical costs need to be considered in cost effectiveness analysis. Eur J Health Econ. 2019;20(1):1–5. https://doi.org/10.1007/s10198-018-0976-0.
4. de Vries LM, van Baal PHM, Brouwer WBF. Future costs in cost-effectiveness analyses: past, present, future. Pharmacoeconomics. 2019;37(2):119–30. https://doi.org/10.1007/s40273-018-0749-8.
5. van Baal P, Morton A, Brouwer W, Meltzer D, Davis S. Should cost effectiveness analyses for NICE always consider future unrelated medical costs? BMJ. 2017;359: j5096. https://doi.org/10.1136/bmj.j5096.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献